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Chlamydia trachomatis, the most common bacterial sexually transmitted disease agent
worldwide, enters a viable, non-dividing and non-infectious state (historically termed
persistence and more recently referred to as the chlamydial stress response) when
exposed to penicillin G in culture. Notably, penicillin G-exposed chlamydiae can reenter the
normal developmental cycle upon drug removal and are resistant to azithromycin-mediated
killing. Because penicillin G is less frequently prescribed than other β-lactams, the clinical
relevance of penicillin G-induced chlamydial persistence/stress has been questioned.
The goal of this study was to determine whether more commonly used penicillins also
induce C. trachomatis serovar E persistence/stress. All penicillins tested, as well as
clavulanic acid, induced formation of aberrant, enlarged reticulate bodies (RB) (called
aberrant bodies or AB) characteristic of persistent/stressed chlamydiae. Exposure to the
penicillins and clavulanic acid also reduced chlamydial infectivity by >95%. None of the
drugs tested significantly reduced chlamydial unprocessed 16S rRNA or genomic DNA
accumulation, indicating that the organisms were viable, though non-infectious. Finally,
recovery assays demonstrated that chlamydiae rendered essentially non-infectious by
exposure to ampicillin, amoxicillin, carbenicillin, piperacillin, penicillin V, and clavulanic acid
recovered infectivity after antibiotic removal. These data definitively demonstrate that
several commonly used penicillins induce C. trachomatis persistence/stress at clinically
relevant concentrations.
Keywords: Chlamydia trachomatis, β-lactam, penicillin, antibiotic susceptibility, chlamydial persistence,
chlamydial stress response, stressed chlamydiae
INTRODUCTION
The most common bacterial sexually transmitted disease (STD)
agent in humans is Chlamydia trachomatis (serovars D-K), with
1,412,791 reported cases in the US in 2011 (Centers for Disease
Control and Prevention, 2011). C. trachomatis genital infection is
often chronic in women, with manifestations ranging from mild
infection to infertility and ectopic pregnancy (Schachter, 1999).
Most women with chlamydia-induced cervicitis are asymp-
tomatic (Schachter et al., 1983) and at higher risk for serious com-
plications. Genital co-infections with Neisseria gonorrhoeae and
C. trachomatis infections are also frequent; in fact, C. trachoma-
tis is historically the most common cause of post-gonococcal
urethritis and cervicitis (PGU/PGC). Azithromycin and tetracy-
cline/doxycycline are currently the treatments of choice for C.
trachomatis infections in adults, though amoxicillin remains a
recommended treatment for infected, pregnant women (Centers
for Disease Control and Prevention, 2010).
C. trachomatis is a Gram-negative, obligate intracellular bac-
teriumwith a biphasic developmental cycle. The infectious, extra-
cellular form (the elementary body or EB) enters host genital
epithelial cells within an endosome. Following fusion of EB-
containing endosomes, EB (0.2μm diameter) develop into larger
(0.8μm), replicative, non-infectious reticulate bodies (RB). RB
use ATP and metabolites from the host cell to grow and subse-
quently divide within a cytoplasmic inclusion. After 30–70 h, the
RB mature into infectious EB and are released from the infected
host cell (Wyrick, 2000).
It has become clear that the “biphasic” view of chlamydia
development is incomplete. Exposure to certain adverse condi-
tions can divert the developmental cycle into a state referred to as
persistence or, more recently, as the chlamydial stress response. In
persistence/stress, the chlamydiae are viable, but non-infectious
(reviewed in Hogan et al., 2004; Wyrick, 2010; Schoborg, 2011).
Penicillin G-exposure is one stressor that induces C. trachoma-
tis to enter this state in culture. Penicillin G-exposed chlamy-
diae can remain persistent/stressed for up to 9 months and,
upon antibiotic removal, can re-enter the normal developmen-
tal cycle (Galasso and Manire, 1961; Matsumoto and Manire,
1970). Persistent/stressed chlamydial inclusions contain enlarged
RBs (abberent bodies or AB), and few infectious EBs (Matsumoto
and Manire, 1970). Persistent/stressed chlamydiae are also viable,
as indicated by: (i) continued synthesis of genomic DNA and
unprocessed 16S rRNA; and (ii) their ability to re-enter the devel-
opmental cycle. However, they do not divide, are non-infectious,
and less metabolically active (reviewed in Hogan et al., 2004;
Wyrick, 2010; Schoborg, 2011). Published data also indicate that
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chlamydiae also enter this altered developmental state in vivo.
Continued chlamydial infections and repeat infections with the
same serovar are common, despite appropriate antibiotic ther-
apy (Patton et al., 1994; Fortenberry et al., 1999; Dean et al.,
2000). Chlamydial AB have been observed in samples from
patients and infected animals (Nanagara et al., 1995; Skowasch
et al., 2003; Pospischil et al., 2009; Rank et al., 2011). Finally,
viable but non-infectious organisms are observed in the gen-
ital tracts of amoxicillin-treated, C. muridarum-infected mice
(Phillips-Campbell et al., 2012).
Although the mechanism by which penicillins exert their anti-
chlamydial effects has been controversial, C. trachomatis does
express 3 penicillin-binding proteins (PBPs) (Barbour et al., 1982;
Storey and Chopra, 2001). More recent data suggest penicillin
G, mecillinam and piperacillin may inhibit chlamydial cell divi-
sion by binding Pbp2 and Pbp3/FtsI (Ouellette et al., 2012).
However, penicillin G and amoxicillin are the only β-lactams
demonstrated to render chlamydiae persistent/stressed using all
generally accepted critera (Galasso andManire, 1961; Matsumoto
and Manire, 1970; Phillips-Campbell et al., 2012). Ampicillin
exposure reduces chlamydial infectivity and alters inclusion mor-
phology (Johnson and Hobson, 1977; Beale et al., 1991; Wolf
et al., 2000; Storey and Chopra, 2001), while mecillinam and
piperacillin induce AB formation (Storey and Chopra, 2001;
Ouellette et al., 2012), suggesting induction of chlamydial persis-
tence/stress. However, the first indication that β-lactams might
not be lethal for developing chlamydiae came from clinical obser-
vations in the 1960s (Holmes et al., 1967; Richmond et al.,
1972).These authors reported frequent cases of C. trachomatis-
mediated PGU/PGC in patients several months following suc-
cessful eradication of N. gonorrhoeae with penicillin therapy. As
a result, in most cases, penicillins are not considered front-line
anti-chlamydial drugs.
MATERIALS AND METHODS
CHLAMYDIA AND HOST CELLS
A human urogenital isolate of C. trachomatis E/UW-5/CX
was obtained from S. P. Wang and C. C. Kuo (University of
Washington, Seattle, WA). This strain was propagated in McCoy
cells and used for all experiments. HeLa cells, a human cervical
adenocarcinoma epithelial cell line (ATCC No. CCL2), were cul-
tivated in growth medium (Minimal Essential Medium (MEM)
with Earle’s salts containing L-glutamine, 10% fetal calf serum
(Atlanta Biologicals) and 1μg/mL gentamicin) at 37◦C and 5%
CO2 on standard tissue culture plates or glass coverslips.
CHLAMYDIAL INFECTION AND ANTIBIOTIC EXPOSURE
Host cell monolayers were either mock-infected (exposed to
2SPG: 0.2M sucrose, 6mM NaH2PO4, 15mM Na2HPO4, 5mM
L-glutamine, pH 7.2) or C. trachomatis-infected at a multiplic-
ity of infection (MOI) of 1, using crude EB stock diluted in
2SPG for 1 h at 35◦C. Monolayers used for minimal inhibitory
concentration (MIC)/immunofluorescent (IFA) or minimal bac-
tericidal concentration (MBC) analyses were then immediately
refed with growth medium plus diluent (ddH2O) or the antibi-
otic of interest and incubated for 54 h at 35◦C. Monolayers
used in all other antibiotic-exposure experiments were first refed
with medium and incubated at 35◦C for 24 h, after which
the supernatant was replaced with medium + diluent or the
antibiotic of interest. Cultures were then harvested for analy-
sis at 30 h post-antibiotic addition, a total of 54 h post-infection
(hpi). In recovery experiments, replicate antibiotic-exposed cul-
tures were washed at 54 hpi, refed with either antibiotic-replete
(non-recovered group) or antibiotic-deficient (recovered group)
medium, and incubated at 35◦C for 3 additional days (a total
of 126 hpi).
FLUORESCENT AND TRANSMISSION ELECTRON MICROSCOPY
IFA and high-contrast transmission electron microscopy (TEM)
analyses were performed as described (Deka et al., 2006).
Fluorescent photomicrographs were taken using a Zeiss Axiovert
S100 microscope/Axiocam camera, and converted to grayscale
using Adobe Photoshop V5.0.
CHLAMYDIAL INFECTIVITY ASSAY
Production of infectious C. trachomatis EB was assayed using a
subpassage titer assay as described (Deka et al., 2006), except that
phosphonoformate was omitted from the medium. The number
of inclusion forming units (IFU)/mL in the undiluted inoculum
was calculated from triplicate determinations.
RNA AND DNA ISOLATION
Total RNA and DNA were isolated simultaneously from exper-
imental samples using the RNeasy Mini (Qiagen) and QIAmp
DNA Blood Mini (Qiagen) kits as described (Deka et al.,
2006). Total RNA and DNA preparations were quantified using
optical density (OD) at 260 and 280 nm; all samples had
OD260/280 ratios >1.9. RNA sample quality was assessed
by using a 2100 Bioanalyzer (Agilent) and the RNA 6000
Nano LabChip kit. All samples had RNA Integrity Numbers
(RINs) >9.0.
REVERSE TRANSCRIPTION, PCR, AND RT-PCR
Reverse transcription of total RNA, PCR, and RT-PCR were per-
formed as described (Deka et al., 2006). PCR and RT-PCR was
performed using purified total cellular DNA or cDNA as tem-
plates, respectively. Control and experimental templates were
diluted from 1/10 to 1/1000 in ddH2O to insure that each reac-
tion was quantified in the linear amplification range. Primer sets
used to amplify the human glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) and chlamydial 16S rRNA genes, as well as for
C. trachomatis unprocessed 16S rRNA transcript have been pub-
lished (Deka et al., 2006). After PCR, all reaction products were
electrophoresed, quantified and normalized as described (Deka
et al., 2006).
STATISTICAL ANALYSES
Statistics were performed using Microsoft Excel. Means were
compared by 2-sample t-test for independent samples. P =
0.05 were considered significant. All plotted values are aver-
ages of three biological replicates ± standard error of the
mean (s.e.m.) and each experiment was performed three times
independently.
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RESULTS
RATIONALE FOR ANTIBIOTIC-EXPOSURE CONDITIONS
Though penicillin G is a characterized chlamydial persistence
inducer, it is less widely used than other β-lactams. Also, as peni-
cillins are no longer recommended for anti-chlamydial therapy
in adults, one might question the relevance of penicillin-induced
chlamydial persistence in vivo. It is important to recognize
that penicillins are commonly utilized to treat other bacterial
infections—with the result that developing chlamydiae within
asymptomatically-infected individuals are exposed to β-lactams
during therapy for other concurrent infections. Thus, the peni-
cillins evaluated in this study were chosen primarily according
to prescription frequency: amoxicillin (AMX), clavulanic acid
(CLA), ampicillin (AMP), and penicillin V (PEN V) were all
among the top 200 most prescribed drugs in the US in 2011
(Bartholow, 2011). Carbenicillin (CAR) and piperacillin (PIP)
were chosen because of their high efficacy for Gram-negative bac-
teria. Aztreonam (ATM), a monobactam, was chosen because
of its structural dissimilarity to penicillin. The cephalosporin
ceftriaxone (CRO) was chosen because it is a recommended treat-
ment for gonococcal infections (Centers for Disease Control and
Prevention, 2010), which often occur simultaneously with C. tra-
chomatis. Finally, cefotaxime (CTX) was chosen to confirm any
effect of CRO on chlamydial development. The standard con-
centration of each drug used (denoted as 1X in Table 1) was
equivalent to the serum concentration obtained after admin-
istration of a standard dose in clinical trials (McEvoy, 2004),
increasing the in vivo relevance of any observed effects.
NO PENICILLIN OF INTEREST INHIBITS INCLUSION FORMATION
To determine whether the antibiotics of interest blocked inclu-
sion formation or EB production, chlamydia-infected cells were
exposed to 10-fold antibiotic dilutions from 1 to 54 hpi. MIC
for the chlamydiae has been variously defined by either inhibi-
tion of inclusion formation (Welsh et al., 1992) or by abnor-
mal inclusion morphology (Storey and Chopra, 2001). Because
identification of “abnormal inclusions” seemed subjective, we
defined the MIC as the minimal drug concentration that pre-
vented inclusion development (Welsh et al., 1992). MBC was
defined as the drug concentration required to reduce infectious
EB production by >99% (Welsh et al., 1992). As no penicillin
tested inhibited inclusion formation, even at 100 times the serum
concentration, MICs could not be calculated (Table 1). In con-
trast, the MIC for tetracycline (TET) was 0.043μg/mL (Table 1),
similar to published values (Welsh et al., 1992). Exposure to all
6 penicillins tested, as well as to CLA, produced small inclusions
FIGURE 1 | Penicillin-exposure alters chlamydial morphology. HeLa
cells were plated on glass coverslips, infected with C. trachomatis and
refed immediately post-infection with growth medium + various dilutions of
each antibiotic of interest. At 54 hpi, infected cells were fixed and stained
with FITC-conjugated anti-C. trachomatis MOMP as described. (A)
Mock-infected cells + ddH2O (diluent). (B) C. trachomatis-infected (Ct)
cells + diluent. (C) C. trachomatis + ATM. (D) C. trachomatis cells + CAR.
(E) C. trachomatis + PIP. (F) C. trachomatis + TET. Panels (B–E) are
representative inclusions photographed at 1000X magnification. Inclusions
in panels (C–F) were drug-exposed at the 1X concentration (Table 1).
Table 1 | The 1X concentrations, MIC and MBC of all drugs used in this study.
Drug Class Serum (1X)* concentration MIC** MBC***
Amoxicillin (AMX) Penicillin 11μg/mL >1100μg/mL 0.011μg/mL
Ampicillin (AMP) Penicillin 3.7μg/mL >370μg/mL 0.037μg/mL
Aztreonam (ATM) Monobactam 1.8μg/mL >180μg/mL >180μg/mL
Carbenicillin (CAR) Penicillin 1.9μg/mL >190μg/mL 0.019μg/mL
Cefotaxime (CTX) Cephalosporin 2.53μg/mL >253μg/mL >253μg/mL
Ceftriaxone (CRO) Cephalosporin 0.93μg/mL >93μg/mL >93μg/mL
Clavulanic acid (CLA) β-lactamase inhibitor 3.5μg/mL >350μg/mL 0.35μg/mL
Penicillin G (PEN G) Penicillin 20U/mL >2000U/mL 0.02U/mL
Penicillin V (PEN V) Penicillin 0.2μg/mL >20μg/mL 0.002μg/mL
Piperacillin (PIP) Penicillin 39μg/mL >3900μg/mL 0.39μg/mL
Tetracycline (TET) Tetracycline 4.3μg/mL 0.043μg/mL ND
*The 1X concentration was defined as the peak serum concentration of each drug obtained in clinical trials after administration of a standard dose (McEvoy, 2004).
**The MIC was defined as the minimal concentration of each drug required to prevent formation of chlamydial inclusions. In most cases, a precise MIC could not
be determined because the highest tested drug concentration (100X) did not prevent inclusion formation.
***The MBC was defined as the minimal concentration of each drug required to reduce infectious EB production in sub-titer assays by >99%. In the case of ATM,
CTX, and CRO, MBC could not be determined because the highest tested drug concentration (100X) did not reduce infectious titer by >99%.
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FIGURE 2 | Penicillin-exposure induces chlamydial AB formation. HeLa
cells were C. trachomatis-infected and incubated in the absence of
antibiotic for 24 h. Infected and uninfected cultures were then refed with
medium containing each antibiotic of interest at the 1X concentrations
(Table 1). Cells were incubated for an additional 30 h (a total of 54 hpi),
fixed and subjected to TEM. (A) Mock-infected cells + ddH2O (diluent). (B)
C. trachomatis-infected (Ct) cells + diluent. (C) C. trachomatis + AMX. (D)
C. trachomatis + AMP. (E) C. trachomatis + ATM. (F) C. trachomatis +
CAR. (G) C. trachomatis + CLA. (H) C. trachomatis + PEN G. (I) C.
trachomatis + PEN V. (J) C. trachomatis + PIP. (K) C. trachomatis + TET.
(L) C. trachomatis + CRO. Morphologically normal RB and EB are indicated
by white and striped arrows respectively. Abberent bodies (AB) are labeled
with black arrows. Each photomicrograph is at 7500X magnification; the
black bar at the lower right of each panel represent 2μm.
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containing large, spherical structures, similar to AB formed dur-
ing persistence/stress (Figures 1D,E, white arrows). In contrast,
diluent- (ddH2O), ATM- and cephalosporin-exposed inclusions
were indistinguishable from each other (Figures 1B,C and data
not shown). Finally, mock-infected controls contained no inclu-
sions (Figure 1A) and TET-exposure prevented inclusion forma-
tion (Figure 1F), as expected. Thus, all penicillins tested altered
inclusion morphology, but did not prevent inclusion develop-
ment.DNA and unprocessed
PENICILLIN-EXPOSURE INDUCES RB MORPHOLOGIC ALTERATIONS
CHARACTERISTIC OF PERSISTENCE/STRESS
PEN G-exposed, persistent/stressed chlamydial RB (termed AB)
have a distinctive morphology (Matsumoto and Manire, 1970).
To determine whether exposure to other β-lactams induces simi-
lar structural alterations, C. trachomatis-infected HeLa cells were
antibiotic-exposed from 24 to 54 hpi and subjected to TEM. This
exposure time was chosen to mimic an in vivo situation in which
chlamydiae are penicillin-exposed after they have initiated devel-
opment. Importantly, C. trachomatis serovar E under identical
culture conditions is primarily in the RB stage, and still suscep-
tible to the effects of penicillin G, up to 44 hpi (Deka et al., 2006,
2007). Inclusions inC. trachomatis-infected, diluent-exposed cells
contained normal RB (white arrow) as well as intermediate bodies
(IB) and EB (striped arrow; Figure 2B). ATM-exposed chlamy-
diae (Figure 2E) were indistinguishable from diluent-exposed
controls. Though occasional AB were observed in CRO- and
CTX-exposed cultures, most RB were normal in appearance and
abundant EBwere observed (Figure 2L and data not shown, white
and striped arrows respectively). In contrast, AMX- (Figure 2C),
AMP- (Figure 2D), CAR- (Figure 2F), PEN V- (Figure 2I), PIP-
(Figure 2J), and CLA- (Figure 2G) exposed chlamydial inclusions
contained swollen, irregular AB (black arrows), and few IBs or
EBs were observed. PENG-exposed chlamydiae were similarmor-
phologically to those exposed to the other penicillins (Figure 2H),
and, as expected, were characteristic of persistent chlamydiae
(Matsumoto and Manire, 1970). Finally, though few IB or EB
were observed in TET-exposed cultures, AB were not observed
(Figure 2K, white arrow). These observations indicate that expo-
sure to commonly prescribed β-lactam antibiotics, as well to CLA,
induce formation of chlamydial AB.
PENICILLINS REDUCE PRODUCTION OF INFECTIOUS EBs AT
PHYSIOLOGICALLY-RELEVANT CONCENTRATIONS
Persistent/stressed chlamydiae, while viable, are non-infectious
(reviewed in Hogan et al., 2004; Wyrick, 2010; Schoborg, 2011).
TEM studies indicated that penicillin-exposed, C. trachoma-
tis-infected cells contained few EB (Figure 2), suggesting that
production of infectious organisms was inhibited by all the peni-
cillins of interest. To confirm these observations, chlamydiae-
infected HeLa monolayers were exposed to each antibiotic from
24 to 54 hpi and subjected to sub-passage titration analyses
(Figure 3). As expected, PEN G-exposure significantly reduced
chlamydial infectivity. Likewise, exposure to AMX, AMP, CAR,
PEN V, PIP, and CLA at the 1X serum concentration reduced
production of infectious C. trachomatis EB by >95% com-
pared to the diluent-exposed, chlamydiae-infected controls. In
FIGURE 3 | Penicillin-exposure significantly reduces chlamydial
infectivity. HeLa cells were C. trachomatis-infected and incubated in the
absence of antibiotic for 24 h. Infected and uninfected cultures were then
refed with medium containing each antibiotic of interest at the 1X
concentrations (Table 1). Thirty hours post-antibiotic addition (54 hpi total),
infected cell lysates were collected and used for infectious titer analyses.
Inclusion counts were averaged and used to calculate inclusion forming units
(IFU)/mL. The average of three biologic replicates from one of three
independent experiments ± s.e.m. is shown. Groups significantly different
from the diluent-exposed, Ct-infected control are indicated by asterisks (∗),
P ≤ 0.05 was considered significant.
contrast, neither ATM- (Figure 3) nor cephalosporin-exposure
(data not shown) significantly reduced chlamydial infectivity. As
expected, production of infectious EB was essentially abolished
by TET-exposure. These data demonstrate that exposure to peni-
cillins or CLA significantly reduces production of infectious EB
from infected cells.
PENICILLIN-EXPOSURE DOES NOT REDUCE ACCUMULATION OF
EITHER C. trachomatis GENOMIC DNA OR UNPROCESSED 16S rRNA
Though non-infectious, persistent/stressed chlamydiae remain
viable and continue to synthesize (and accumulate) both genomic
DNA and unprocessed 16s rRNA (Gerard et al., 1998, 2001).
To assess chlamydial viability, chlamydiae-infected, HeLa mono-
layers were exposed to each antibiotic under the conditions
described above. Host GAPDH DNA, chlamydial 16S DNA and
chlamydial unprocessed 16S rRNA were quantified as described
(Deka et al., 2006) and representative gels used for quantifi-
cation of relative C. trachomatis 16S DNA and unprocessed
16S rRNA accumulation are shown in Figure 4A. Statistical
analysis (Figure 4B) indicated that there was no significant
reduction in either chlamydial genome accumulation or unpro-
cessed 16S rRNA accumulation in any of the antibiotic-exposed,
infected cultures compared to that in diluent-exposed, infected
cells. These data are consistent with previous observations that
C. trachomatis L2 genomic DNA accumulation is unaffected
by PEN G-exposure (Lambden et al., 2006). They also sug-
gest that penicillin-exposed chlamydiae continue chromosomal
and unprocessed 16S rRNA accumulation and are, therefore,
viable.
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FIGURE 4 | Penicillin-exposure does not reduce genomic DNA or pre-16S
rRNA accumulation. Total DNA and RNA from 1X antibiotic-exposed,
infected cells was subjected to semi-quantitative PCR (or RT-PCR) using
primers specific for human GAPDH (DNA), chlamydial 16S rRNA (DNA), and
chlamydial unprocessed 16S rRNA transcripts (RNA). (A) Representative PCR
gel images. Amplification of + control DNA dilutions are shown to the left.
(B) Plots of chlamydial genomic DNA amplimer quantity normalized to host
genomes (left) and pre-ribosomal RNA-specific amplimer quantity normalized
to chlamydial genomes (right). The average of three independent biologic
replicates from one of three independent experiments ± s.e.m. is shown.
None of the experimental groups were significantly different from the
diluent-exposed, infected control at P ≤ 0.05.
PENICILLIN-EXPOSED CHLAMYDIAE RESUME PRODUCTION OF
INFECTIOUS EB AFTER DRUG REMOVAL
One important characteristic of persistent/stressed chlamydiae
is that they can re-enter the normal developmental cycle
and produce infectious EB when the stressor is removed
(reviewed in Hogan et al., 2004; Wyrick, 2010; Schoborg, 2011).
Therefore, antibiotic recovery experiments were carried out as
described in the methods. As expected, the yield of infec-
tious chlamydiae immediately after the initial 30 h antibiotic-
exposure (Figures 5B–E,G–I) was much lower than that from
diluent-exposed, infected controls (Figures 5A,F). Chlamydial
titers obtained after 3 days of additional antibiotic-exposure
(“non-recovered” cultures) remained low in all cases. In con-
trast, significantly increased chlamydial titers were observed in
AMX-, AMP-, CAR-, PEN V-, PIP-, and CLA-exposed cultures
after the 3 day recovery period (recovered samples), compared to
those obtained either immediately after initial drug-exposure or
from parallel “non-recovered” cultures (Figures 5B–E,G,H). As
expected, PEN G-exposed chlamydiae recovered infectivity after
drug removal as well (Figure 5I). These data indicate that chlamy-
diae exposed to commonly prescribed penicillins can recover
infectivity when the drugs are removed. Notably, the total amount
of infectivity recovered after antibiotic removal was different for
each drug tested.
DISCUSSION
AMX-, AMP-, CAR-, PENV-, PIP-, and CLA-exposed chlamydiae
exhibit defining characteristics of persistent/stressed organisms
(reviewed in Hogan et al., 2004; Wyrick, 2010; Schoborg, 2011).
They are viable (as evidenced by continued genome and pre-16S
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FIGURE 5 | Penicillin-induced stress/persistence is reversible. Replicate
cultures of HeLa cells were infected and antibiotic-exposed at concentrations
10-fold higher than the MBC for each drug (Table 1) using the timing scheme
described in Figure 3. At 30 h post-antibiotic addition (54 hpi total), one set of
cultures was harvested for “pre-recovery” EB titration as in Figure 3.
Duplicate antibiotic-exposed and control cultures were washed, refed with
either antibiotic-replete (non-recovered samples) or antibiotic-deficient
(recovered samples) growth medium and allowed to recover for 3 additional
days (a total of 126 hpi). These cultures were then processed for EB titration.
Note that each drug-exposure experiment was divided into two separate
sets. The diluent-exposed control for panels (B–E) is shown in panel (A) and
the diluent-exposed control for panels (G–I) is shown in panel (F). The
average of three biologic replicates ± s.e.m. is shown and p ≤ 0.05 was
considered significant. Single asterisks (∗) indicate titers that are significantly
higher than those observed in the pre-recovery cultures within each
drug-exposure group. Double asterisks (∗∗) denote titers that are significantly
increased compared to the non-recovered cultures within each group. The
experiment shown is one of three independent experiments.
rRNA accumulation and the ability to recover infectivity after
drug removal) but non-infectious (as shown by reduced chlamy-
dial titer). These drugs also induce AB formation, which is consis-
tent persistence/stress induction (Matsumoto and Manire, 1970).
Thus, these commonly prescribed β-lactams induce chlamydial
persistence/stress in culture at physiologically-relevant concen-
trations. The CDC currently recommends either azithromycin
or AMX for treatment of chlamydia-infected, pregnant women
(Centers for Disease Control and Prevention, 2010). However,
with recent reports linking azithromycin to adverse cardiac out-
comes (Ray et al., 2012), more physicians may elect to use
AMX in this situation. Whether or not AMX-treated, C. tra-
chomatis-infected women have a higher risk of subsequent tubal
factor infertility is currently unknown. However, because: (i)
chlamydiae can recover from AMX-induced persistence/stress
in culture; and (ii) resumption of shedding is observed after
AMX-treatment cessation in chlamydia-infected mice (Phillips-
Campbell et al., 2012), it seems reasonable to conclude that
AMX-treated, infected women may remain at risk for chronic
infection and reproductive complications. Thus, if AMX is used,
it is important that chlamydial eradication be confirmed post-
therapy, as per CDC recommendations (Centers for Disease
Control and Prevention, 2010).
CLA, a β-lactam originally isolated from Streptomyces
clavuligerus, is a strong β-lactamase inhibitor and is used clini-
cally to increase β-lactam activity against penicillinase-producing
bacterial strains (Reading and Cole, 1977). CLA also has direct
antimicrobial activity, albeit weaker than that of other β-lactams.
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Interestingly, the reported CLA MBC for E. coli is 25μg/mL
(Neu and Fu, 1978), more than 70 times higher than that for
C. trachomatis (Table 1). Because CLA binds E. coli PBP2 (Spratt
et al., 1977) and C. trachomatis expresses a PBP2 homolog that
may function in RB division (Ouellette et al., 2012), it seems
likely that CLA induces chlamydial persistence/stress by inhibiting
PBP2 function. This would be consistent with published observa-
tions that the PBP2-specific drug, mecillinam, also induces AB
formation and reduces EB production (Storey and Chopra, 2001;
Ouellette et al., 2012). Our data (Table 1) also indicate that C. tra-
chomatis serovar E is resistant to ATM, CTX and CRO, at least at
physiologically achievable concentrations.
Approximately 50% of total antibiotics used in human
medicine are β-lactams, most of which are aminopenicillins -
like AMX and AMP (Kümmerer and Henninger, 2003; Goossens
et al., 2005). Since there are about 1.5 million reported new
chlamydial infections per year in the US (Centers for Disease
Control and Prevention, 2011), up to 75% of which are asymp-
tomatic (Detels et al., 2011), brief episodes of β-lactam-induced
persistence/stress may occur in many patients during treatment
for other bacterial infections. There are also other routes by
which chlamydia-infected hosts could be chronically exposed
to low levels of β-lactam and other antibiotics. For exam-
ple, there is widespread, low-level β-lactam contamination of
milk, meat and other agricultural products. The risks posed
by such contamination, most notably penicillin allergy and
promotion of antibiotic resistance, have been recognized for
decades (Welch, 1956). Antibiotics and their degradation prod-
ucts (DPs) are also found in ground water, the most com-
monly identified of which are macrolides, sulfonamides, fluoro-
quinalones and tetracyclines (Heberer, 2002; Kolpin et al., 2002).
Notably, exposure to low concentrations of erythromycin (a
macrolide), ciprofloxacin and ofloxacin (both fluoroquinalones)
also induces persistence/stress in both C. pneumoniae and C. tra-
chomatis (Dreses-Werringloer et al., 2000, 2001; Gieffers et al.,
2004). Though most β-lactams are rapidly converted to DPs
by UV light and chlorination, some AMX-DPs, like AMX
S-oxide, are environmentally stable and retain an intact β-
lactam ring (Gozlan et al., 2010). Therefore, DPs of β-lactams
or other antibiotics consumed in treated water could induce
chlamydial persistence/stress in vivo. However, the effect of
antibiotic DPs on chlamydial development, if any, is currently
unknown.
Treatment failure is a significant problem in human chlamy-
dial infections (Horner, 2006; Pitt et al., 2013). For example,
post-treatment C. trachomatis positivity is reported in 10-15%
of women on recommended treatment regimens (Wang et al.,
2005). Significantly, penicillin G-exposed, persistent/stressed C.
trachomatis serovar E is resistant to azithromycin killing in
culture (Wyrick and Knight, 2004). Likewise, IFN-exposed,
persistent/stressed C. trachomatis is more resistant to doxycy-
cline (Reveneau et al., 2005). Azithromycin and ofloxacin also
do not eradicate persistent/stressed C. pneumoniae in culture
(Kutlin et al., 1999). Finally, induction of persistence/stress using
AMX increases azithromycin treatment failure in C. muridarum-
infected mice (Phillips-Campbell et al., 2014). These studies
suggest that in vivo persistence/stress could be one mechanism
by which chlamydiae resist antimicrobial therapy in vivo. Thus,
given the widespread medical use of these antibiotics, as well as
their presence in food and water, β-lactam-induced chlamydial
persistence/stress may have significantly more in vivo relevance
than previously assumed.
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